News
Undeterred by FDA setback, GSK snaps up Spero antibiotic
GSK is paying $66 million upfront to license rights to Spero Therapeutics novel antibiotic tebipenem Hbr, unswayed by the FDA's decision earlier this year not to approve the drug for adults
